R&D Sponsored Type 1 diabetes: The importance of early screening and diagn... This article was organised, funded, and reviewed by Sanofi.
News Compounders cast adrift after semaglutide shortage ends The FDA has said there is no longer a shortage in the US market for Novo Nordisk's GLP-1 agonist semaglutide, ending sales of compounded forms.
News First biosimilar fast-acting insulin reaches US market Sanofi has claimed FDA approval for the first biosimilar of Novo Nordisk's rapid-acting insulin analogue Novolog.
News Liva buys Momenta to bolster digital health platform Liva Healthcare has acquired Momenta to create one of the largest providers of digital healthy lifestyle services to the NHS in England.
News Novo rises on Wegovy sales leap, but warns of a slowdown Novo Nordisk is expecting greater competition and pricing pressure in the obesity and diabetes sectors this year.
R&D Pharma holds it breath for ’25 as the sun shines on JP Morga... The JP Morgan Healthcare Conference is seen as a barometer for the life sciences industry – and, going into this year’s event, the forecast for the year was particularly grim.
R&D LSX2026: On a therapeutic vision for ocular disease, with Al... Alexander Gebauer, co-founder & executive chairman of Galimedix Therapeutics, discusses transforming treatment of major neurodegenerative eye diseases
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
